While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are two cash-producing companies that leverage their financial strength to beat the competition and one that may face some trouble.
One Stock to Sell:
Service International (SCI)
Trailing 12-Month Free Cash Flow Margin: 13.3%
Founded in 1962, Service International (NYSE: SCI) is a leading provider of death care products and services in North America.
Why Is SCI Risky?
- Demand for its offerings was relatively low as its number of funeral services performed has underwhelmed
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 14.4% for the last two years
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Service International is trading at $78.52 per share, or 18.3x forward P/E. Check out our free in-depth research report to learn more about why SCI doesn’t pass our bar.
Two Stocks to Watch:
Netflix (NFLX)
Trailing 12-Month Free Cash Flow Margin: 25.4%
Launched by Reed Hastings as a DVD mail rental company until its famous pivot to streaming in 2007, Netflix (NASDAQ: NFLX) is a pioneering streaming content platform.
Why Do We Watch NFLX?
- Has the opportunity to boost monetization through new features and premium offerings as its global streaming paid memberships have grown by 15.6% annually over the last two years
- Excellent EBITDA margin of 30.4% highlights the efficiency of its business model, and its rise over the last few years was fueled by some leverage on its fixed costs
- Free cash flow margin increased by 16.2 percentage points over the last few years, giving the company more capital to invest or return to shareholders
Netflix’s stock price of $86.93 implies a valuation ratio of 21.1x forward EV/EBITDA. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Amgen (AMGN)
Trailing 12-Month Free Cash Flow Margin: 23.1%
Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ: AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.
Why Does AMGN Stand Out?
- Annual revenue growth of 12.3% over the last two years beat the sector average and underscores the unique value of its offerings
- Economies of scale give it more fixed cost leverage than its smaller competitors
- Robust free cash flow margin of 27.7% gives it many options for capital deployment
At $336.02 per share, Amgen trades at 4.8x forward price-to-sales. Is now the time to initiate a position? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
